Clinical, genetic profile and disease progression of sarcoglycanopathies in a large cohort from India: high prevalence of SGCB c.544A > C
- 13 April 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in neurogenetics
- Vol. 23 (3), 187-202
- https://doi.org/10.1007/s10048-022-00690-9
Abstract
The clinico-genetic architecture of sarcoglycanopathies in Indian patients is reported only as short series. In the present study, we aimed to investigate the clinical picture, genetic basis, and disease progression of patients genetically confirmed to have sarcoglycanopathy. Next-generation sequencing was performed in 68 probands with suspected sarcoglycanopathy. A total of 35 different variants were detected in the sarcoglycan genes in 68 probands (M = 37; age range, 5–50 years). Consanguinity was present in 44 families. Thirty-two variants are predicted to be pathogenic/likely pathogenic, among which 25 (78.13%) are reported, and 7 (21.87%) are novel. The clinical diagnosis was confirmed in a total of 64 (94.12%) probands with biallelic variations [SGCA(n=18); SGCB(n=34); SGCG(n=7); SGCD(n=5)]. The most common mutation was c.544A > C (p.Thr182Pro) in SGCB, and detected in 20 patients (29.42%). The majority of pathogenic mutations are homozygous (n = 30; 93.75%). Variants in 4 cases are of uncertain significance. Thirty-three patients lost ambulation at a mean age of 15.12 ± 9.47 years, after 7.76 ± 5.95 years into the illness. Only 2 patients had cardiac symptoms, and one had respiratory muscle involvement. The results from this study suggest that mutations in SGCB are most common, followed by SGCA, SGCG, and SGCD. The novel variations identified in this study expand the mutational spectrum of sarcoglycanopathies. To the best of our knowledge, this is the first study from India to describe a large cohort of genetically confirmed patients with sarcoglycanopathy and report its disease progression.This publication has 66 references indexed in Scilit:
- Exome Sequencing and Functional Validation in Zebrafish Identify GTDC2 Mutations as a Cause of Walker-Warburg SyndromeAmerican Journal of Human Genetics, 2012
- Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modificationsHuman Mutation, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- Fast and accurate long-read alignment with Burrows–Wheeler transformBioinformatics, 2010
- Sarcoglycanopathy: Clinical and histochemical characteristics in 66 patientsNeurology India, 2010
- Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic populationBrain, 2009
- Spectrum of mutations in sarcoglycan genes in the Mumbai region of western India: High prevalence of 525del TNeurology India, 2009
- Mannosidase I inhibition rescues the human α-sarcoglycan R77C recurrent mutationHuman Molecular Genetics, 2008
- Sarcoglycanopathies: A clinico-pathological studyNeurology India, 2007
- Practice patterns of neurology in India: Fewer hands, more workNeurology India, 2007